Lineage Cell Therapeutics, Inc. (LCTX) Stock Price

LCTXStock

$1.11−8.26%52W

Market Cap$280.73M

P/E—

PEG Ratio10.64

Div yield—

Beta1.55

LCTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-50.94%

Price vs S&P 500 (4W)-1.54%

PEG Ratio10.64

VGM Score41.63

Book Value / Share (Quarterly)$0.24

P/TBV (Annual)29.94x

Revenue Growth (3Y)61.12%

Cash Flow / Share (Quarterly)$-0.10

Price vs S&P 500 (YTD)-46.35%

Gross Margin (TTM)94.11%

Net Profit Margin (TTM)-263.65%

EPS (TTM)$-0.14

10-Day Avg Trading Volume0.91M

EPS Excl Extra (TTM)$-0.14

Revenue Growth (5Y)33.57%

EPS (Annual)$-0.28

ROI (Annual)-142.39%

Gross Margin (Annual)92.50%

Net Profit Margin (5Y Avg)-506.99%

Cash / Share (Quarterly)$0.20

Revenue Growth QoQ (YoY)-58.44%

ROA (Last FY)-56.43%

Revenue Growth TTM (YoY)-37.15%

EBITD / Share (TTM)$-0.11

ROE (5Y Avg)-28.77%

Operating Margin (TTM)-285.11%

Cash Flow / Share (Annual)$-0.08

P/B Ratio4.42x

P/B Ratio (Quarterly)5.36x

Net Income / Employee (Annual)$-882,400

EV / Revenue (TTM)19.51x

Net Interest Coverage (TTM)-17.84x

ROA (TTM)-30.87%

EV / EBITDA (TTM)7.66x

EPS Incl Extra (Annual)$-0.28

Current Ratio (Annual)5.20x

Quick Ratio (Quarterly)6.44x

3-Month Avg Trading Volume1.33M

52-Week Price Return-8.26%

Revenue / Employee (TTM)$112,461,500,000

Tangible BV / Share (Quarterly)$0.12

P/S Ratio (Annual)30.11x

Asset Turnover (Annual)0.09x

52-Week High$2.09

Operating Margin (5Y Avg)-339.82%

EPS Excl Extra (Annual)$-0.28

CapEx CAGR (5Y)-20.81%

Tangible BV CAGR (5Y)-36.58%

26-Week Price Return-39.01%

Quick Ratio (Annual)4.99x

13-Week Price Return-16.54%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.61x

Enterprise Value$232.04M

Revenue / Share Growth (5Y)23.45%

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-19.58%

Revenue / Employee (Annual)$124,200

Inventory Turnover (Annual)7.40x

Pretax Margin (Annual)-260.28%

Cash / Share (Annual)$0.23

3-Month Return Std Dev45.19%

Gross Margin (5Y Avg)88.93%

Net Income / Employee (TTM)$-448,100

ROE (Last FY)-142.61%

Net Interest Coverage (Annual)-16.50x

EPS Basic Excl Extra (Annual)$-0.28

P/FCF (TTM)14.83x

Receivables Turnover (TTM)20.26x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.14

Receivables Turnover (Annual)0.58x

ROI (TTM)-71.04%

P/S Ratio (TTM)19.32x

Pretax Margin (5Y Avg)-535.76%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$0.05

Free OCF CAGR (5Y)-38.10%

Price vs S&P 500 (52W)-26.82%

EPS Growth TTM (YoY)53.54%

Year-to-Date Return-33.53%

5-Day Price Return1.83%

EPS Normalized (Annual)$-0.28

ROA (5Y Avg)-22.63%

Net Profit Margin (Annual)-240.20%

Month-to-Date Return2.78%

Cash Flow / Share (TTM)$-0.13

EBITD / Share (Annual)$-0.16

Operating Margin (Annual)-276.50%

LT Debt / Equity (Annual)0.11x

ROI (5Y Avg)-25.56%

LT Debt / Equity (Quarterly)0.14x

EPS Basic Excl Extra (TTM)$-0.14

P/TBV (Quarterly)11.18x

P/B Ratio (Annual)8.63x

Inventory Turnover (TTM)7.40x

Pretax Margin (TTM)-284.20%

Book Value / Share (Annual)$0.18

Price vs S&P 500 (13W)-18.50%

Beta1.55x

P/FCF (Annual)262.32x

Revenue / Share (TTM)$0.05

ROE (TTM)-71.14%

52-Week Low$1.00

vGradeC

gGradeD

mGradeC

vgmGradeC

LCTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.03	$0.01	+133.33%(+$0.04)
Q4 2025	Mar 5, 2026	-$0.04	$0.00	+100.00%(+$0.04)
Q3 2025	Nov 6, 2025	-$0.03	-$0.13	-358.88%(-$0.10)
Q2 2025	Aug 12, 2025	-$0.03	-$0.13	-358.88%(-$0.10)

LCTX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.07

4.08

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
LCTXLineage Cell Therapeutics, Inc.	C	D	C	$1.11
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement and cell/drug delivery therapies for degenerative diseases. Key pipeline candidates include OpRegen for age-related macular degeneration, OPC1 for spinal cord injuries, VAC2 for non-small cell lung cancer, and cell therapies for hearing and vision loss.